Exclusive Summary

• Originator's core patents have expired, fully opening up global market access and creating vast distribution opportunities.
• Listed on the WHO Essential Medicines List (EML), it serves as a cornerstone and first-line therapy for Multiple Myeloma (MM) and Erythema Nodosum Leprosum (ENL) with stable rigid demand globally.
• Stringent regulatory requirements due to severe teratogenic risks (e.g., REMS) create a higher entry barrier, making generic competition less fierce than typical generic drugs.
• Backed by China's cost-effective supply chain, the available 25mg/50mg strengths provide significant price competitiveness, empowering local distributors to win tenders and secure high profitability.